NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

Bevacizumab的生物相似藥:市場機會、銷售量、價格趨勢、臨床實驗趨勢分析 (2025年)

Bevacizumab Biosimilar Market Opportunity , Sales, Price & Clinical Trials Insight 2025

出版商 KuicK Research 商品編碼 974418
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Bevacizumab的生物相似藥:市場機會、銷售量、價格趨勢、臨床實驗趨勢分析 (2025年) Bevacizumab Biosimilar Market Opportunity , Sales, Price & Clinical Trials Insight 2025
出版日期: 2020年12月07日內容資訊: 英文 120 Pages
簡介

本報告提供Bevacizumab生物相似藥的市場、臨床實驗趨勢相關分析,彙整市場基本結構和產品的概要,品牌藥和生物相似藥的競爭狀態,主要的成藥銷售趨勢,主要的開發平台醫藥品和臨床實驗的發展情形,今後的市場規模、價格水準趨勢預測,主要企業的簡介和主要產品、競爭情形等資訊,為您概述為以下內容。

目錄

第1章 Bevacizumab:市場現狀

第2章 Bevacizumab:償付方案

第3章 Bevacizumab成藥:市場分析

  • 劑量、專利、價格趨勢分析:品牌藥/生物相似藥
    • Avastin
    • Mvasi
    • Zirabev
    • Aybintio
  • Avastin:銷售量分析

第4章 Bevacizumab生物相似藥:市場分析

  • 目前市場情境
  • 市場機會及未來預測

第5章 Bevacizumab生物相似藥的目前臨床實驗情形、展望

  • 國家
  • 適應症
  • 患者市場區隔
  • 企業

第6章 Bevacizumab生物相似藥臨床實驗的進展:各相 (各期)

  • 不明
  • 藥物研發
  • 前臨床
  • 臨床
  • 第一階段
  • 第二階段
  • 第二階段/第三階段
  • 第三階段
  • 核准前
  • 已通過核准

第7章 Bevacizumab成藥 (品牌藥/生物相似藥)的臨床性考察

  • Avastin
  • Bevacizumab生物相似藥:KRABEVA
  • Bevacizumab生物相似藥:BYVASDA
  • Bevacizumab生物相似藥:Bevax
  • Bevacizumab生物相似藥:ZIRABEV
  • Bevacizumab生物相似藥:Mvasi
  • Bevacizumab生物相似藥:Bryxta
  • Bevacizumab生物相似藥:Bevatas
  • Bevacizumab生物相似藥:Cizumab
  • Bevacizumab生物相似藥:Versavo
  • Bevacizumab生物相似藥:Lumiere

第8章 Bevacizumab、生物相似藥市場:未來展望

第9章 競爭情形

  • Amgen
  • AryoGen Pharmed
  • Biothera
  • Boehringer Ingelheim
  • Centus Biotherapeutics
  • Henlius Biotech
  • Innovent Biologics
  • Mylan
  • mAbxience
  • Outlook Therapeutics
  • Pfizer
  • Prestige Biopharma
  • Roche
  • Samsung Bio
  • TOT Biopharm
目錄

"Bevacizumab Biosimilar Market Opportunity, Sales, Price & Clinical Trials Insight 2025" Report Highlights:

  • Bevacizumab Market Opportunity: > USD 12 Billion by 2025
  • Bevacizumab Biosimilar in Clinical Trials: > 25 Biosimilars
  • Bevacizumab Biosimilar Available in Market: >8 Biosimilars
  • Bevacizumab Market Spread: US & Europe Share > 60%
  • Bevacizumab Branded v/s Biosimilar Insight
  • Avastin & Bevacizumab Biosimilar Price, Sales & Dosage Insight
  • Bevacizumab Patent Insight by Indication & Year

Bevacizumab is among the cusp of getting recognized as one of the most prominent drugs for the treatment of multiple types of cancer. Being an innovative approach of immunotherapy capable of neutralizing vascular endothelial growth factor, it got its fast-end approval as a first anti-angiogenic therapy by the regulatory bodies for the benefit of millions of cancer patients. The parent bio-pharmaceutical company of the drug is F. Hoffmann-La Roche AG and in the year 2004, the drug got recognized as one of the promising immunotherapy drugs as a first-line therapy when combined with intravenous 5-fluorouracil-based chemotherapy for the treatment of the patients suffering from metastatic colorectal cancer. Application wise, the drug has extended its wings for the treatment of colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. Such huge segmentation of the global bevacizumab biosimilar drug tends to deliver the large percentage it is contributing to the global cancer biosimilar market.

The emergence of bevacizumab biosimilar drug for the cancer patients have burnt all the issues that were recorded in the past few years i.e. comparison of the biosimilar drugs with the reference drugs. The 20 years of experience of bevacizumab biosimilar drug in the market has achieved high comfort level and rise in overall cancer therapeutics market that was not imagined by the researchers and the patients. The drug market is witnessed to deliver high growing healthcare benefits as the opportunities related with the cancer treatment is apparently more when compared with the treatment expenses of other biological cancer treatments.

The global market of the drug has created a jinxed for the biosimilar market, thus making the researchers and the patients lean towards this mode of treatment as one of the most prominent types. In addition to this, the overall drug market in a very short period of time has come up with high valued and worthy outcome to the parent company and it is seeking towards more robust performance with novel trends in the upcoming years. The market in a very short period of time has been successful in establishing a primary goal for over-shadowing the expensive nature of the cancer treatment towards a novel approach that is cheap, affordable and as beneficial as the reference product.

The analysis of the bevacizumab biosimilar drug performance has landed high market expectations and a classification of the drug market that is 100% accurate in terms of mechanism of action, chemical properties and many more. The association of the market with strong and prominent research team of the parent company is all focused on making the drug as a solo treatment regimen with high quality in combination with other therapies so that all the current challenges could be over-come in short period of time. In addition, it is estimated that the biosimilar drug market of bevacizumab has been able to introduce a unique revolution in the entire biosimilar market, thus resulting in creating a landscape that is successful and central component to trillion dollars cancer therapeutics market.

Table of Contents

1. Bevacizumab - Current Market Overview

2. Bevacizumab - Reimbursement Scenario

3. Bevacizumab - Commercial Availability

  • 3.1. Dosage, Patent & Price Analysis - Branded v/s Biosimilar
    • 3.1.1. Avastin
    • 3.1.2. Mvasi
    • 3.1.3. Zirabev
    • 3.1.4. Aybintio
  • 3.2. Avastin - Sales Analysis

4. Bevacizumab Biosimilar Market Analysis

  • 4.1. Current Market Scenario
  • 4.2. Market Opportunities & Forecast

5. Global Bevacizumab Biosimilar Ongoing Clinical Trials Outlook

  • 5.1. Country
  • 5.2. Indication
  • 5.3. Patient Segment
  • 5.4. Organization

6. Global Bevacizumab Biosimilar Clinical Insight By Phase

  • 6.1. Unknown
  • 6.2. Research
  • 6.3. Preclinical
  • 6.4. Clinical
  • 6.5. Phase-I
  • 6.6. Phase-II
  • 6.7. Phase-II/III
  • 6.8. Phase-III
  • 6.9. Preregistration
  • 6.10. Registered

7. Marketed Bevacizumab Branded & Biosimilar Drug Clinical Insight

  • 7.1. Avastin
  • 7.2. Bevacizumab Biosimilar - KRABEVA
  • 7.3. Bevacizumab Biosimilar - BYVASDA
  • 7.4. Bevacizumab Biosimilar - Bevax
  • 7.5. Bevacizumab Biosimilar - ZIRABEV
  • 7.6. Bevacizumab Biosimilar - Mvasi
  • 7.7. Bevacizumab Biosimilar - Bryxta
  • 7.8. Bevacizumab Biosimilar Bevatas
  • 7.9. Bevacizumab Biosimilar - Cizumab
  • 7.10. Bevacizumab Biosimilar - Versavo
  • 7.11. Bevacizumab Biosimilar - Lumiere

8. Bevacizumab Biosimilar Market - Future Outlook

9. Competitive Landscape

  • 9.1. Amgen
  • 9.2. AryoGen Pharmed
  • 9.3. Biothera
  • 9.4. Boehringer Ingelheim
  • 9.5. Centus Biotherapeutics
  • 9.6. Henlius Biotech
  • 9.7. Innovent Biologics
  • 9.8. Mylan
  • 9.9. mAbxience
  • 9.10. Outlook Therapeutics
  • 9.11. Pfizer
  • 9.12. Prestige Biopharma
  • 9.13. Roche
  • 9.14. Samsung Bio
  • 9.15. TOT Biopharm

List of Figures

  • Figure 1-1: Global - Bevacizumab Market Size (US$ Billion), 2017 - 2019
  • Figure 1-2: Global - Bevacizumab Market Opportunity (US$ Billion), 2020 - 2025
  • Figure 1-3: Bevecezumab - Market Size by Region (%), 2019
  • Figure 1-4: Bevecezumab - Market Size by Type of Product (%), 2019
  • Figure 2-1: US - Average Selling Price (ASP) of Bevacizumab Products (US$/10mg), 2020
  • Figure 2-2: US - Reimbursed Amount of Bevacizumab Products (US$/10mg), 2020
  • Figure 3-1: Avastin - FDA Approval Year by Indication
  • Figure 3-2: Avastin - Patent Expiration Year by Region
  • Figure 3-3: Avastin - Price for a Supply of 4ml & Price per Unit ml Solution for Injection (US$), December'2020
  • Figure 3-4: Avastin - Price for a Supply of 16ml & Price per Unit ml Solution for Injection (US$), December'2020
  • Figure 3-5: Avastin - Price for a Supply of 10 & Price for Single 4ml Solution for Injection (US$), December'2020
  • Figure 3-6: Avastin - Price for a Supply of 10 & Price for Single 16ml Solution for Injection (US$), December'2020
  • Figure 3-7: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for NSCLC & Metastatic Cervical Cancer (US$), December'2020
  • Figure 3-8: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December'2020
  • Figure 3-9: Avastin - Duration of Treatment of Recurrent Glioblastoma & Renal Cell Carcinoma as Combinational & Monotherapy (Weeks), December'2020
  • Figure 3-10: Avastin - Cost of Single Treatment Cycle & Annual Treatment Cost for Recurrent Glioblastoma & Renal Cell Carcinoma (US$), December'2020
  • Figure 3-11: Avastin's Biosimilar - FDA Approval Year
  • Figure 3-12: Avastin's Biosimilar - EMA Approval Year
  • Figure 3-13: Mvasi - Price for 4ml Supply & Price per ml of Intravenous Solution (US$), December'2020
  • Figure 3-14: Mvasi - Price for 16 ml Supply & Price per Unit of Intravenous Solution (US$), December'2020
  • Figure 3-15: Zirabev - Price for 4ml Supply & Price per unit of Intravenous Solution (US$), December'2020
  • Figure 3-16: Zirabev - Price for 16 ml Supply & Price per unit of Intravenous Solution (US$), December'2020
  • Figure 3-17: Aybintio - Price for 4ml Supply & Price per Unit of Intravenous Solution (GBP/US$), December'2020
  • Figure 3-18: Aybintio - Price for 16 ml Supply & Price per unit of Intravenous Solution (GBP/US$), December'2020
  • Figure 3-19: Bevaczumab - Price Comparision for Single Supply of 4 ml Intravenous Solution (US$), December'2020
  • Figure 3-20: Bevaczumab - Price Comparision for Single Supply of 16 ml Intravenous Solution (US$), December'2020
  • Figure 3-21: Avastin - Annual Sales Value (US$/CHF Billion), 2017 - 2019
  • Figure 3-22: Global - Avastin Quarterly Sales Value (US$ Billion), 2018 & 2019
  • Figure 3-23: US - Avastin Quarterly Sales Value (US$ Million), 2019
  • Figure 3-24: Avastin - Annual Sales Share by Region (US$ Billion), 2019
  • Figure 3-25: Avastin - Sales Share by Region (%), 2019
  • Figure 3-26: Global - Avastin Quarterly Sales Value (US$ Million), Q1 - Q3, 2020
  • Figure 3-27: Avastin - Sales Share by Region (US$ Billion), Q1 - Q3, 2020
  • Figure 3-28: Avastin - Sales Share by Region (%), 2019
  • Figure 4-1: Global - Bevacizumab Biosimilar Market Size by Product (US$ Million), 2019
  • Figure 4-2: Investigational Bevacizumab Biosimilars & Their Manufacturer
  • Figure 4-3: Global - Zirabev Market Opportunity (US$ Million), 2019 - 2026
  • Figure 4-4: Global - Mvasi Market Opportunity (US$ Million), 2019 - 2025
  • Figure 4-5: US - Mvasi Market Opportunity (US$ Million), 2019 - 2025
  • Figure 4-6: Global - Bevacizumab Biosimilar Market Opportunity (US$ Billion), 2020 - 2025
  • Figure 5-1: Global - Bevacizumab Biosimilar Clinical Trials by Country, 2020 - 2025
  • Figure 5-2: Global - Bevacizumab Biosimilar Clinical Trials by Indication, 2020 - 2025
  • Figure 5-3: Global - Bevacizumab Biosimilar Clinical Trials by Patient Segment, 2020 - 2025
  • Figure 5-4: Global - Bevacizumab Biosimilar Clinical Trials by Organization, 2020 - 2025
  • Figure 6-1: Global - Bevacizumab Biosimilar Clinical Trials by Phase, 2020 - 2025
  • Figure 6-2: Global - Bevacizumab Biosimilar Clinical Trials by Phase, 2020 - 2025